Core Viewpoint - CoreWeave has secured $8.5 billion in financing to expand its artificial intelligence cloud platform, driven by increasing demand for computing power [1][2]. Financing Details - The total equity and debt financing commitments for CoreWeave in the past 12 months amount to approximately $28 billion [2]. - Initially, CoreWeave can borrow about $7.5 billion, with the option to increase to $8.5 billion as data-center assets stabilize [2]. - The loan is set to mature in March 2032 [2]. Transaction Structure - The financing facility was co-structured and book-run by Morgan Stanley and MUFG, with Goldman Sachs and JPMorgan as additional coordinating lead arrangers [3]. - The loan was anchored by Blackstone Credit & Insurance and involved participation from various global financial institutions, asset managers, and insurance investors [3].

Core Viewpoint - Nvidia's $2 billion investment in Marvell Technology signals strong confidence in Marvell's role in the AI infrastructure ecosystem, particularly in addressing GPU interconnect challenges and enhancing data center capabilities [2][3][6]. Company Overview - Marvell Technology received a $2 billion direct investment from Nvidia, integrating deeper into Nvidia's AI ecosystem [2][6]. - Marvell's fiscal 2026 revenue reached $8.195 billion, reflecting a 42% year-over-year increase, with management guiding for fiscal 2027 revenue to exceed $11 billion [2][10]. - The acquisition of Celestial AI adds photonic fabric technology to Marvell's offerings, addressing GPU interconnect challenges [2][8]. Competitive Positioning - Marvell competes with Broadcom and other connectivity suppliers, but its unique combination of custom silicon, Ethernet solutions, and photonic technology provides a differentiated position in the data-center infrastructure layer [2][10]. - The investment from Nvidia validates Marvell's critical role in enabling AI data center scaling beyond just GPU capabilities [3][11]. Financial Performance - Marvell reported record fiscal 2026 results, with non-GAAP earnings rising 81% to $2.84 per share and fourth-quarter revenue hitting $2.219 billion, up 22% from the prior year [9][10]. - Management anticipates over 30% growth for fiscal 2027, with data-center revenue expected to accelerate [10][12]. Market Outlook - The forward P/E ratio for Marvell is approximately 22.9x, which is below its historical average and reasonable given projected growth [12]. - Analyst consensus ranges from Moderate Buy to Strong Buy, with average 12-month price targets near $117, suggesting a 25% upside from recent levels around $88 [12][13].

Group 1 - Baron Capital's "Baron Financials ETF" experienced a decline of 2.22% in Q4 2025, while the FactSet Global FinTech Index fell by 7.19% and the MSCI USA Financials Index gained 2.07% [1] - Since its inception, the Fund has achieved an annualized return of 10.21%, compared to 2.55% for the benchmark index and 11.97% for the MSCI USA Financials Index [1] - The Fund transitioned from a mutual fund to an ETF in December 2025, maintaining its growth-focused investment strategy on financial and financial-related companies [1] Group 2 - Houlihan Lokey, Inc. (NYSE:HLI) is highlighted as a key stock in the Fund's portfolio, specializing in M&A, capital markets, and financial advisory services [2] - As of March 30, 2026, Houlihan Lokey's stock closed at $141.05, with a one-month return of -12.99% and a 52-week decline of 14.05% [2] - The company has a market capitalization of approximately $9.84 billion [2] Group 3 - The performance of Houlihan Lokey was negatively impacted by overexposure to Robinhood Markets and a slowdown in restructuring activity due to improving macroeconomic conditions and lower interest rates [3] - Despite the challenges, Houlihan Lokey's M&A and valuation advisory businesses, which account for over 75% of its operations, experienced a 24% pretax earnings growth in the recent quarter [3]

Core Viewpoint - Seagate Technology (STX) has experienced a decline of over 20% from its recent all-time high, despite previously being rated as a buy due to strong EPS growth potential, attractive valuation, and healthy technical indicators [1]. Group 1 - The stock was rated as a buy in early December based on its strong EPS growth rate potential [1]. - The decline of more than 20% indicates a significant pullback from its peak performance [1]. - The company maintains an attractive valuation and generally healthy technicals, which could present future investment opportunities [1].

Core Viewpoint - Visa has received a new Buy rating from Loop Capital with a price target of $387, indicating strong analyst confidence in the company's growth potential despite recent stock price declines [2][5]. Company Performance - Visa's stock was trading at $299.54 as of March 30, reflecting a 13.55% decline year-to-date, yet the company continues to show consistent double-digit revenue growth [3][5]. - In Q1 FY2026, Visa reported net revenue of $10.90 billion, a 14.6% year-over-year increase, surpassing estimates by 1.98% [5]. - Non-GAAP EPS for the same quarter was $3.17, exceeding the consensus estimate of $3.1423, continuing a pattern of earnings beats [5]. - Operating cash flow reached $6.780 billion in Q1 FY2026, up 25.65% year-over-year, with data processing revenue growing 17% to $5.544 billion [6]. Market Position and Analyst Sentiment - The broader Wall Street consensus shows strong support for Visa, with 29 analysts rating the stock as Buy, seven as Strong Buy, and three as Hold, with no Sell ratings [5]. - The consensus price target among analysts is $398.91, indicating a favorable outlook compared to Loop Capital's target of $387 [7]. Strategic Initiatives - Visa is executing its "payments hyperscaler" strategy, which aims to enhance its technology and infrastructure in the payments sector [5][6]. - CEO Ryan McInerney emphasized ongoing investments in Visa's service stack to redefine payment possibilities [6]. Recent Challenges - Visa shares recently hit a 52-week low amid macroeconomic concerns and the loss of its NFL sponsorship to American Express, creating a valuation gap [7]. - The stock currently trades at a trailing P/E of 28x and a forward P/E of 23x, significantly lower than its 52-week high of $373.33 [7]. Capital Returns - Visa's capital return program includes the repurchase of approximately 11 million shares at an average price of $342.13 per share in Q1 FY2026, with $21.1 billion remaining in its buyback authorization [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pinterest, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's financial health and advertising revenue [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Pinterest and its executives made false or misleading statements regarding the company's advertising revenues and the impact of U.S. tariffs on its business operations [4]. - Pinterest's financial results revealed a significant decline in expected revenues, with Q4 revenue guidance of $1.325 billion falling short of the consensus estimate of $1.34 billion, leading to a stock price drop of 21.76% on November 5, 2025 [5][6]. - A global restructuring plan was announced on January 27, 2026, which included a workforce reduction of less than 15% and anticipated pre-tax restructuring charges of approximately $35 million to $45 million, resulting in a further stock price decline of 9.61% [7]. - The financial results for the fiscal year ended December 31, 2025, showed quarterly revenue of $1.32 billion, below the consensus estimate of $1.33 billion, and a Q1 2026 revenue guidance of $951 million to $971 million, also below expectations, causing a stock price drop of 16.83% [8][9]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased Pinterest securities between February 7, 2025, and February 12, 2026, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options for participating in a federal securities class action [1][2]. - The deadline for investors to seek the role of lead plaintiff in the class action is set for May 29, 2026 [2]. - The lead plaintiff will be the investor with the largest financial interest in the relief sought and will oversee the litigation on behalf of the class [10].

Core Insights - Once Upon a Farm is expanding its product portfolio with five new organic offerings aimed at children, including Meat and Meat & Bone Broth pouches, Legume Blends, Smoothies with Protein & Probiotics, and Power Wheels snack bars [2][3][4] Product Expansion - The new product line includes refrigerated, cold-pressure protected meat pouches for babies, marking the brand's first entry into this category [3][4] - Smoothies with Protein & Probiotics are designed for older kids, each containing 4g of protein and probiotics to support immune health [3][5] - Power Wheels are soft and chewy snack bars made with 4g of protein and whole-grain oats, aimed at children aged 4 years and older [3][5][12] Nutritional Focus - The Meat and Meat & Bone Broth pouches provide at least 4g of protein from high-quality meats, including grass-fed beef and free-range chicken, with no added growth hormones or antibiotics [5][12] - Research indicates that 72% of parents prefer fresh, refrigerated meat purees for their babies, highlighting a market demand for high-quality, nutritious baby food [4][5] - Nearly half (46%) of U.S. parents with children ages three and younger consider protein an important attribute when selecting foods for their children [7] Market Positioning - Once Upon a Farm aims to support families through various stages of childhood nutrition, from introducing solids to providing snacks for school [4][12] - The company emphasizes its commitment to organic, non-GMO products that contain no added sugar or artificial ingredients, appealing to health-conscious parents [10][12]

NO INVESTMENT ADVICE The content on this Site is provided for information purposes only and does not constitute investment advice, a personal recommendation, an offer or solicitation to buy or sell securities, or any other regulated activity. It should not be relied upon as the basis for any investment decision. Before making any investment decision, you should: Read the relevant prospectus, term sheet, subscription agreement, or other offering documentation in full Consider whether the investment is suit ...

Core Insights - Biogen has acquired Apellis Pharmaceuticals for $5.6 billion, enhancing its drug portfolio with two approved medications [1] - The acquisition has significantly boosted Apellis' stock, which saw a triple-digit increase following the announcement [1] Company Overview - Biogen's acquisition of Apellis adds Empaveli and Syfovre to its pipeline, with Empaveli approved for treating three conditions, including two rare kidney diseases, and Syfovre targeting an eye disease [1] - Last year, the combined sales of Empaveli and Syfovre contributed to Apellis' revenue growth, indicating strong market potential for these drugs [1]

Core Viewpoint - Warren Buffett expressed regret over selling a portion of Berkshire Hathaway's Apple shares too soon, highlighting the importance of long-term investment strategies [2][3]. Investment Position - Berkshire Hathaway began acquiring Apple shares around 2016, with the stake peaking at over $170 billion, before being reduced by approximately two-thirds by the end of 2024, leaving a valuation of around $40 billion [4]. Financial Performance - Despite the reduction in stake, Berkshire made over $100 billion pretax on the Apple investment, which remains its largest single investment [5]. - Apple's recent financial results show Q1 FY2026 revenue of $143.756 billion, a 15.65% increase year-over-year, with iPhone revenue reaching an all-time high of $85.269 billion, up 23.3% year-over-year [6][7]. Market Position - Apple's installed base has surpassed 2.5 billion active devices, contributing to significant growth in services revenue, which reached $30.013 billion [6][7]. - Since the start of 2024, Apple shares have increased by 34.23%, currently trading around $246.63, with an analyst consensus price target of $295.31 [7].